ArticleMolecular therapy. Advances2026
Universal strategy to generate lentiviral vectors encoding lethal proteins.
Article in Molecular therapy. Advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lentiviral vectors have emerged as a versatile and robust platform for gene therapy. However, their use for delivering toxic genes has been hindered by challenges related to packaging lentiviral genomes that encode inherently lethal transgenes. In this study, we introduce a novel multi-layered approach to overcome this obstacle. Our results show that combining a regulatable promoter, an inverted orientation of the lethal transgene expression cassette, and CRISPR-based inhibition to repress vector transgene transcription effectively reduces toxicity in producer cells, enabling the efficient production of high-titer lentiviral vectors expressing lethal proteins. Notably, these lentiviral vectors were able to deliver transgenes encoding pro-apoptotic proteins or toxins that induced cell death in cancer cells, providing a translational proof of concept for therapeutic payload delivery. Overall, this work establishes an innovative framework that expands the utility of the lentiviral platform for the controlled delivery of cytotoxic factors in gene therapy applications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.